E. J. Czerwiński

9.8k total citations · 2 hit papers
156 papers, 3.5k citations indexed

About

E. J. Czerwiński is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, E. J. Czerwiński has authored 156 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Orthopedics and Sports Medicine, 45 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in E. J. Czerwiński's work include Bone health and osteoporosis research (54 papers), Bone health and treatments (44 papers) and Bone Metabolism and Diseases (22 papers). E. J. Czerwiński is often cited by papers focused on Bone health and osteoporosis research (54 papers), Bone health and treatments (44 papers) and Bone Metabolism and Diseases (22 papers). E. J. Czerwiński collaborates with scholars based in Poland, Belgium and United States. E. J. Czerwiński's co-authors include E. Michael Lewiecki, Cesar Libanati, Neil Binkley, Felicia Cosman, Serge Ferrari, Henry G. Bone, Jonathan D. Adachi, Andreas Grauer, Akimitsu Miyauchi and Daria B. Crittenden and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

E. J. Czerwiński

111 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

2016 1.1k citations Felicia Cosman, Jonathan D. Adachi et al. profile →
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

2017 662 citations Henry G. Bone, Rachel B. Wagman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. J. Czerwiński Poland	21	2.5k	1.9k	1.4k	565	249	156	3.5k
Stéphanie Kaiser Germany	27	1.6k 0.6×	686 0.4×	727 0.5×	1.0k 1.8×	290 1.2×	81	3.5k
Louis‐Georges Ste‐Marie Canada	20	706 0.3×	527 0.3×	414 0.3×	290 0.5×	179 0.7×	48	1.6k
Rachel I. Gafni United States	36	470 0.2×	771 0.4×	878 0.6×	756 1.3×	333 1.3×	78	3.7k
Elizabeth A. Streeten United States	24	328 0.1×	409 0.2×	544 0.4×	260 0.5×	220 0.9×	64	1.9k
Agnès Linglart France	41	475 0.2×	987 0.5×	2.1k 1.5×	717 1.3×	636 2.6×	243	6.0k
Donald W. Morrish Canada	31	609 0.2×	248 0.1×	739 0.5×	697 1.2×	55 0.2×	78	3.0k
Xuhao Yang China	17	244 0.1×	442 0.2×	663 0.5×	80 0.1×	50 0.2×	35	1.6k
David Chandler United States	32	199 0.1×	354 0.2×	630 0.4×	340 0.6×	120 0.5×	107	3.4k
Giuseppe Colella Italy	26	294 0.1×	804 0.4×	271 0.2×	813 1.4×	247 1.0×	152	2.4k
Madelon Bracke Netherlands	25	229 0.1×	250 0.1×	513 0.4×	182 0.3×	92 0.4×	46	2.3k

Countries citing papers authored by E. J. Czerwiński

Since Specialization

Citations

This map shows the geographic impact of E. J. Czerwiński's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. J. Czerwiński with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. J. Czerwiński more than expected).

Fields of papers citing papers by E. J. Czerwiński

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. J. Czerwiński. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. J. Czerwiński. The network helps show where E. J. Czerwiński may publish in the future.

Co-authorship network of co-authors of E. J. Czerwiński

This figure shows the co-authorship network connecting the top 25 collaborators of E. J. Czerwiński. A scholar is included among the top collaborators of E. J. Czerwiński based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. J. Czerwiński. E. J. Czerwiński is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Yoon‐Sok, Bente Langdahl, E. J. Czerwiński, et al.. (2024). SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. Bone. 192. 117371–117371. 1 indexed citations

Reginster, Jean‐Yves, E. J. Czerwiński, Krzysztof Wilk, et al.. (2024). Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporosis International. 35(11). 1919–1930. 6 indexed citations

Lewiecki, E. Michael, E. J. Czerwiński, Chris Recknor, et al.. (2023). Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study. Journal of Bone and Mineral Research. 38(10). 1404–1414. 10 indexed citations

Czerwiński, E. J., José Cardona, Chris Recknor, et al.. (2020). The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. Journal of Bone and Mineral Research. 37(12). 2435–2442. 23 indexed citations

Bone, Henry G., Maria Luisa Brandi, Jacques P. Brown, et al.. (2016). TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL. Open Repository and Bibliography (University of Liège). 1 indexed citations

Marcinowska-Suchowierska, Ewa, Piotr Głuszko, J Badurski, et al.. (2015). Treatment of osteoporosis in Poland – availability and reasons for lack of implementation. Postępy Nauk Medycznych. 2 indexed citations

Ferrari, Serge, Cesar Libanati, S. Adámi, et al.. (2015). Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment. Open Repository and Bibliography (University of Liège). 5 indexed citations

Papapoulos, Socrates E., Kurt Lippuner, C. Roux, et al.. (2014). EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST FIVE YEARS OF THE FREEDOM EXTENSION. Open Repository and Bibliography (University of Liège). 12 indexed citations

Ferrari, Serge, Cesar Libanati, S. Adámi, et al.. (2014). Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment. Open Repository and Bibliography (University of Liège). 1 indexed citations

10.

Recknor, Chris, E. J. Czerwiński, Henry G. Bone, et al.. (2013). Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy. Obstetrics and Gynecology. 121(6). 1291–1299. 110 indexed citations

11.

Czerwiński, E. J., et al.. (2012). Epidemiology of osteoporotic fractures. Jagiellonian University Repository (Jagiellonian University). 9 indexed citations

12.

Bone, Henry G., R. Chapurlat, Cesar Libanati, et al.. (2011). Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. Open Repository and Bibliography (University of Liège). 3 indexed citations

13.

Orwoll, Eric, Bente Langdahl, R. Chapurlat, et al.. (2011). A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO. Open Repository and Bibliography (University of Liège). 1 indexed citations

14.

Papapoulos, Socrates E., Z. Man, Dan Mellström, et al.. (2011). FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION. Data Archiving and Networked Services (DANS). 9 indexed citations

15.

Chapurlat, R., Socrates E. Papapoulos, Henry G. Bone, et al.. (2010). Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial. Open Repository and Bibliography (University of Liège). 2 indexed citations

16.

Felsenberg, Dieter, et al.. (2009). Efficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study.. Open Repository and Bibliography (University of Liège). 8 indexed citations

17.

Charuta, Anna, et al.. (2009). QUANTITATIVE COMPARISON OF THE PARAMETERS OF THE SPONGIOUS SUBSTANCE OF THE BILATERAL PROXIMAL PHALANX OF THOROUGHBRED HORSES. Bulletin of the Veterinary Institute in Pulawy. 53(4). 759–764. 1 indexed citations

18.

Badurski, J, E. J. Czerwiński, & Ewa Marcinowska-Suchowierska. (2008). Osteoporosis – fracture risk estimation Status Quo Arte Anno 2007/2008: Review of positions of World Health Organisation (WHO), European Medicine Agency (EMEA), European Society Of Clinical And Economic Aspects Of Osteoporosis And Osteoartritis (ESEAO), International Osteoporosis Foundation (IOF), Polish Foundation Of Osteoporosis (PFO) and Polish Osteoartrology Society (PTOA). Postępy Nauk Medycznych. 1 indexed citations

19.

Marczyński, Wojciech, et al.. (2008). The principles of prophylaxis, diagnosis and treatment of osteoporotic bone fractures. Postępy Nauk Medycznych. 1 indexed citations

20.

Czerwiński, E. J., et al.. (2007). Digital assessment of radiograms of the spongy structure of the proximal phalanx of Thoroughbreds and Arabian horses.. Medycyna Weterynaryjna. 63. 1443–1447. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact